Skip to main content

Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms.

Publication ,  Journal Article
Weiss, V; Dueber, J; Wright, JP; Cates, J; Revetta, F; Parikh, AA; Merchant, NB; Shi, C
Published in: World J Gastrointest Oncol
August 15, 2016

AIM: To investigate the role of the Wnt/β-catenin pathway in pancreatic neuroendocrine neoplasms (PanNENs). METHODS: Tissue microarrays containing 88 PanNENs were immunohistochemically labeled with antibodies to β-catenin, E-cadherin, adenomatous polyposis coli (APC), chromogranin and synaptophysin. One case had only metastatic tumors resected, whereas others (n = 87) received pancreatectomy with or without partial hepatectomy. Pathology slides, demographic, clinicopathologic, and follow up data were reviewed. Patients' demographics, clinicopathologic features, and immunohistochemical results from 87 primary tumors were compared between patients with low stage (stage I/II) and high stage (stage III/IV) tumors. In addition, correlation of immunohistochemical results from primary tumors with disease-specific survival (DSS) was evaluated. RESULTS: Strong membranous β-catenin staining in the primary tumor was observed in all 13 stage III/IV PanNENs as compared to 47% (35/74) of stage I/II tumors (P < 0.01). However, the strong membranous β-catenin staining was unassociated with tumor grade or DSS. Decreased membranous β-catenin staining was associated with decreased membranous E-cadherin labeling. Nuclear β-catenin staining was seen in 15% (2/13) of stage III/IV PanNENs as compared to 0% (0/74) of stage I/II tumors (P = 0.02). The case with metastasectomy only also showed nuclear β-catenin staining. Two of the three cases with nuclear β-catenin staining were familial adenomatous polyposis (FAP) patients. Lack of APC expression was seen in 70% (57/81) of the cases, including the 3 cases with nuclear β-catenin staining. Expression of E-cadherin and APC in primary tumor was not correlated with tumor grade, tumor stage, or disease specific survival. CONCLUSION: The Wnt/β-catenin pathway was altered in some PanNENs, but did not Impact DSS. PanNENs in FAP patients demonstrated nuclear β-catenin accumulation and loss of APC.

Duke Scholars

Published In

World J Gastrointest Oncol

DOI

ISSN

1948-5204

Publication Date

August 15, 2016

Volume

8

Issue

8

Start / End Page

615 / 622

Location

China
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weiss, V., Dueber, J., Wright, J. P., Cates, J., Revetta, F., Parikh, A. A., … Shi, C. (2016). Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms. World J Gastrointest Oncol, 8(8), 615–622. https://doi.org/10.4251/wjgo.v8.i8.615
Weiss, Vivian, Julie Dueber, Jesse P. Wright, Justin Cates, Frank Revetta, Alexander A. Parikh, Nipun B. Merchant, and Chanjuan Shi. “Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms.World J Gastrointest Oncol 8, no. 8 (August 15, 2016): 615–22. https://doi.org/10.4251/wjgo.v8.i8.615.
Weiss V, Dueber J, Wright JP, Cates J, Revetta F, Parikh AA, et al. Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms. World J Gastrointest Oncol. 2016 Aug 15;8(8):615–22.
Weiss, Vivian, et al. “Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms.World J Gastrointest Oncol, vol. 8, no. 8, Aug. 2016, pp. 615–22. Pubmed, doi:10.4251/wjgo.v8.i8.615.
Weiss V, Dueber J, Wright JP, Cates J, Revetta F, Parikh AA, Merchant NB, Shi C. Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms. World J Gastrointest Oncol. 2016 Aug 15;8(8):615–622.

Published In

World J Gastrointest Oncol

DOI

ISSN

1948-5204

Publication Date

August 15, 2016

Volume

8

Issue

8

Start / End Page

615 / 622

Location

China